Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter
682 clinical trials found
Clinical trials

RESPONDER-HF

Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)

No longer recruiting

RETHINK-ALZ

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s Disease (NCT04994483)

Currently recruiting

REVERS-PVD

Unravelling the reversibility of pulmonary vascular disease in HFpEF, aortic stenosis and CTEPH after intervention: the REVERS-PVD study (Trial Not Registered)

Currently recruiting

REVIVE

A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy (NCT05953480)

Currently recruiting

RIBFIX_ADVANTAGE

Evaluation of the RibFix™ Advantage Rib Fixation System for Surgical Repair of Rib Fractures (Trial Not Registered)

Currently recruiting

RLY-2608-101

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (NCT05216432)

Currently recruiting

ROCKET

Reduction Of Chronic Post-surgical Pain with Ketamine - ROCKet Trial (ACTRN12617001619336)

No longer recruiting

ROCKET-ASCEND

A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) (NCT05882877)

No longer recruiting

RPC01-3201

INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372)

Currently recruiting

RPC01-3202

A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)

Currently recruiting

RPC01-3203

A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)

Currently recruiting

RPC01-3204

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (NCT03467958)

Currently recruiting

S-BAN

Evaluating the effectiveness of sodium butyrate for treatment of anorexia nervosa in individuals aged 16 and over - an open-label proof of concept study (ACTRN12624000368538p)

Currently recruiting

SABR-COMET 10

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)

No longer recruiting

SABR-COMET 3

A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)

Currently recruiting

SAD-AF

Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)

Currently recruiting

SAFER-TAVI

Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)

Currently recruiting

SCAN-CA

Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)

Previously thought of as a very rare condition, cardiac amyloidosis is increasingly being recognised as a cause of heart failure. Cardiac amyloidosis is caused by proteins depositing into the heart, leading to scarring. If this scarring occurs in the electrical system of the heart, the patient may require a pacemaker. It is currently unknown what proportion of patients that require pacemakers have cardiac amyloidosis. This trial is trying to determine the prevalence of cardiac amyloidosis in patients requiring pacemakers.
Currently recruiting

SEAFARER

Subscalp EEG Augmentation For Accuracy and Reliability in Epilepsy Reviews (ACTRN12625000231448)

Currently recruiting

SeaLAND

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma (SeaLAND) (ACTRN12620000291987)

Currently recruiting
26 27 28 29 30